These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27769671)

  • 21. Quinazoline-based hydroxamic acid derivatives as dual histone methylation and deacetylation inhibitors for potential anticancer agents.
    Zheng H; Dai Q; Yuan Z; Fan T; Zhang C; Liu Z; Chu B; Sun Q; Chen Y; Jiang Y
    Bioorg Med Chem; 2022 Jan; 53():116524. PubMed ID: 34847495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel Conjugated Quinazolinone-Based Hydroxamic Acids: Design, Synthesis and Biological Evaluation.
    Vu TK; Thanh NT; Minh NV; Linh NH; Thao NTP; Nguyen TTB; Hien DT; Chinh LV; Duc TH; Anh LD; Hai PT
    Med Chem; 2021; 17(7):732-749. PubMed ID: 32310052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
    Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
    Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors.
    Zhu Y; Chen X; Wu Z; Zheng Y; Chen Y; Tang W; Lu T
    Arch Pharm Res; 2012 Oct; 35(10):1723-32. PubMed ID: 23139122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis, Biological Evaluation, and Computer-Aided Drug Designing of New Derivatives of Hyperactive Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitors.
    Zhang S; Huang W; Li X; Yang Z; Feng B
    Chem Biol Drug Des; 2015 Oct; 86(4):795-804. PubMed ID: 25763653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploration of certain 1,3-oxazole- and 1,3-thiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
    Anh DT; Hai PT; Huong LT; Park EJ; Jun HW; Kang JS; Kwon JH; Dung DTM; Anh VT; Hue VTM; Han SB; Nam NH
    Bioorg Chem; 2020 Aug; 101():103988. PubMed ID: 32534346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
    Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
    Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
    Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
    Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
    He R; Chen Y; Chen Y; Ougolkov AV; Zhang JS; Savoy DN; Billadeau DD; Kozikowski AP
    J Med Chem; 2010 Feb; 53(3):1347-56. PubMed ID: 20055418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-aryl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents: synthesis, bioevaluation and docking study.
    Huong TT; Dung do TM; Oanh DT; Lan TT; Dung PT; Loi VD; Kim KR; Han BW; Yun J; Kang JS; Kim Y; Han SB; Nam NH
    Med Chem; 2015; 11(3):296-304. PubMed ID: 25256241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and evaluation of novel N-hydroxybenzamides/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and antitumor agents.
    Hieu DT; Anh DT; Tuan NM; Hai PT; Huong LT; Kim J; Kang JS; Vu TK; Dung PTP; Han SB; Nam NH; Hoa ND
    Bioorg Chem; 2018 Feb; 76():258-267. PubMed ID: 29223029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities.
    Yang F; Peng S; Li Y; Su L; Peng Y; Wu J; Chen H; Liu M; Yi Z; Chen Y
    Org Biomol Chem; 2016 Feb; 14(5):1727-35. PubMed ID: 26732459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and evaluation of novel hybrids between 4-anilinoquinazolines and substituted triazoles as potent cytotoxic agents.
    Le-Nhat-Thuy G; Dinh TV; Pham-The H; Nguyen Quang H; Nguyen Thi N; Dang Thi TA; Hoang Thi P; Le Thi TA; Nguyen HT; Nguyen Thanh P; Le Duc T; Nguyen TV
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3741-3747. PubMed ID: 30337229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.
    Chu-Farseeva YY; Mustafa N; Poulsen A; Tan EC; Yen JJY; Chng WJ; Dymock BW
    Eur J Med Chem; 2018 Oct; 158():593-619. PubMed ID: 30243158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel 2-[thio]acetamide linked quinazoline/1,2,4-triazole/chalcone hybrids: Design, synthesis, and anticancer activity as EGFR inhibitors and apoptotic inducers.
    Abdelkhalek AS; Kothayer H; Soltan MK; Ibrahim SM; Elbaramawi SS
    Arch Pharm (Weinheim); 2024 Jul; 357(7):e2300627. PubMed ID: 38593298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
    Xie R; Li Y; Tang P; Yuan Q
    Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
    Hou J; Li Z; Fang Q; Feng C; Zhang H; Guo W; Wang H; Gu G; Tian Y; Liu P; Liu R; Lin J; Shi YK; Yin Z; Shen J; Wang PG
    J Med Chem; 2012 Apr; 55(7):3066-75. PubMed ID: 22435669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
    Chao SW; Chen LC; Yu CC; Liu CY; Lin TE; Guh JH; Wang CY; Chen CY; Hsu KC; Huang WJ
    Eur J Med Chem; 2018 Jan; 143():792-805. PubMed ID: 29223096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking.
    Elkamhawy A; Farag AK; Viswanath AN; Bedair TM; Leem DG; Lee KT; Pae AN; Roh EJ
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5147-54. PubMed ID: 26475520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells.
    Ling Y; Guo J; Yang Q; Zhu P; Miao J; Gao W; Peng Y; Yang J; Xu K; Xiong B; Liu G; Tao J; Luo L; Zhu Q; Zhang Y
    Eur J Med Chem; 2018 Jan; 144():398-409. PubMed ID: 29288941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.